HOME >> MEDICINE >> NEWS
Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

(PHILADELPHIA) -- The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial. The findings, if backed by larger studies, could have important implications for designing personalized treatments for this very dangerous type of prostate cancer, the researchers say.

The team of scientists including first author Jose Moreno, M.D., clinical associate professor of urology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and the Kimmel Cancer Center at Jefferson looked at circulating tumor cells (CTCs) in 240 men with metastatic prostate cancer that failed hormone-depletion therapy. They compared levels prior to chemotherapy and after two to five weeks of treatment. They found that those men with more than five tumor cells per blood sample had a worse prognosis than those who had fewer cells. One half of the patients with more than five CTCs lived at least 10 months, whereas half of the men with fewer tumor cells lived substantially longer 21 months.

Dr. Moreno presents the trials findings June 4, 2007 at the annual meeting of the American Society of Clinical Oncology in Chicago.

The results of the 65-site trial also showed that those patients who underwent chemotherapy and whose CTC number went down fared better and had a more favorable prognosis. That is, the level of response to chemotherapy was reflected in the CTC level, notes Dr. Moreno. The numbers held up even after up to 20 weeks of treatment. If chemotherapy doesnt reduce the CTC level, its information that enables the physician to change the drug regimen or perhaps stop treatment, he says.

Dr. Moreno notes that the prostate specific antigen has been a powerful biomarker for cancer presence and a useful way to gauge treatment effectiveness for years, though it has some flaws. He thinks that th
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
4-Jun-2007


Page: 1 2

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. ENDEAVOR III Trial reports key findings on new-generation stent
4. NIH names Clinical Trial Units for the Microbicide Trials Network
5. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
6. The Public Library of Science launches the new open access journal PLoS Clinical Trials
7. Trial shows vaccine against cervical cancer provides long-term protection
8. Trial shows malaria vaccine could protect young children from disease for 18 months
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
Breaking Medicine Technology:
Cached News: